Skip to main content
. 2017 Apr 25;66(9):1153–1162. doi: 10.1007/s00262-017-1989-8

Fig. 1.

Fig. 1

Kaplan–Meier curves for all patients. a Progression-free survival (PFS)for the three groups (p1, comparison between three groups; P2, Pembrolizumab vs. Pembrolizumab + Ipilimumab). b PFS for ipilimumab monotherapy and pembrolizumab-based therapy. c Overall survival (OS) for three groups